Health

STAT+: Pharmalittle: We’re reading about Dems eyeing Trump MFN deals, fewer drug launches in Europe, and more

Read full article at source ↗

Based on a feed excerpt; full article content has not been acquired. Source evidence retrieved 11/11/2026, 22:06:25 UTC.

Briefings

STAT reports that incoming Democratic committee chairs are investigating most-favored nation drug pricing agreements between pharmaceutical companies and the Trump administration. This investigation is expected to become a top health care oversight priority once Democrats gain control of the Senate in January. The article notes that the Trump administration previously proposed a plan to increase European drug prices, which has resulted in a 27% drop in new drug releases across Europe over the last 17 months compared to the period before the plan was announced.

Key points

• Incoming Democratic chairs of key committees are investigating most-favored nation drug pricing agreements between drugmakers and the Trump administration.
• A 27% drop in new drug releases across European countries occurred over the last 17 months since the Trump administration's plan to increase European drug prices was implemented.

Context

The article discusses the political shift where Democratic committee members are now prioritizing investigations into drug pricing deals between companies and the Trump administration, following the administration's previous plan to raise European drug prices.

Limitations

Data on the 27% drop in new drug releases is from a market-research firm and covers the last 17 months; specific dates for the drop are not provided, and the impact of the investigation on future drug launches remains unmeasured.

Generated by Bittrees-hosted qwen35-2b sha256:aaf42c8b7c3c on 12/11/2026, 03:00:42 UTC. Based on publisher-provided feed evidence; may not cover the full original article. Check the source for details.

View archived briefing on IPFS
bafybeifgbpsuqekok5kvtlkaxqxgmdzlrdtiywexk7sd64u5sm4kywerjy